Kinase Inhibitors: The Reality Behind the Success-Reference-Cited by-同舟云学术

Kinase Inhibitors: The Reality Behind the Success

Published:2017-10-10 Issue:5 Volume:102 Page:726-730
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Jeon Jae Yoon¹,Sparreboom Alex¹,Baker Sharyn D.¹

Affiliation:

1. Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy and Comprehensive Cancer Center; Ohio State University; Columbus Ohio USA

Funder

National Cancer Institute

OSU Comprehensive Cancer Center using Pelotonia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference13 articles.

1. FDA-approved small-molecule kinase inhibitors;Wu;Trends. Pharmacol. Sci.,2015

2. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors;Drenberg;Clin. Pharmacol. Ther.,2013

3. The protein kinase complement of the human genome;Manning;Science,2002

4. Targeting cancer with small molecule kinase inhibitors;Zhang;Nat. Rev. Cancer,2009

5. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs;Wu;Drug. Discov. Today,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

2. Role of c-Src in Carcinogenesis and Drug Resistance;Cancers;2023-12-20

3. May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?;International Journal of Molecular Sciences;2022-12-21

4. Pharmacology of Small‐Molecule Anticancer Agents;Holland‐Frei Cancer Medicine;2022-10-21

5. Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s disease;Expert Opinion on Therapeutic Targets;2022-06-02